Vaccine prevention of maternal cytomegalovirus infection.

By R. Pass, Changpin Zhang, A. Evans, T. Simpson, W. Andrews, Meei-Li W Huang, L. Corey, Janet Hill, E. Davis, C. Flanigan and 1 more. New England Journal of Medicine, 2009

670 citations recorded by the source corpus.

Subfields: Epidemiology, Microbiology, Ophthalmology

View Paper: https://www.semanticscholar.org/paper/0dce4b7c388c4ca7756740c4fa918ba83ed1a876

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. S. Dollard
2. M. Cannon
3. S. L. Bate
4. Arnold Mitnitski

Citations in the corpus

• Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection (2010, background): “This population of susceptible women could be protected from primary infection by an effective CMV vaccine [10].”
• Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. (2013, positive): “A recombinant gB vaccine with MF59 adjuvant was shown to induce neutralizing antibodies (105) and prevent infection (106).”
• Aging, frailty and age-related diseases (2010, background): “A prophylactic vaccine against CMV has recently been developed (Pass et al. 2009) but eradicating this virus would be a major long-term public health undertaking, unlikely ever to be accomplished.”
• Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004. (2010, background): “Several target populations have been proposed for future vaccines, including women of reproductive age [22], preadolescents [23], and children [24].”
• Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta‐analysis (2019, background): “Vaccine studies have been conducted in seronegative and seropositive women.(27,28) Second, the results may help predict the incidence of CMV infection and disease after solid organ transplant which may originate from the donor or the recipient.”
• The “Silent” Global Burden of Congenital Cytomegalovirus (2013, methodology): “A recent phase II trial evaluated the efficacy of a recombinant genetically modified gB protein in a novel adjuvant, MF59 (189), in seronegative women and found a modest ( 50%) reduction in the rate of primary maternal infection in the vaccinated group compared to the placebo group (190).”